Arisaph Pharmaceuticals, Inc. - Product Pipeline Review - 2015

  • ID: 3230993
  • Company Profile
  • 36 pages
  • Global Markets Direct
1 of 4
Arisaph Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

This, ‘Arisaph Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the Arisaph Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Arisaph Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Arisaph Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Arisaph Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Arisaph Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Arisaph Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Arisaph Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Arisaph Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Arisaph Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arisaph Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Arisaph Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Arisaph Pharmaceuticals, Inc. Snapshot
Arisaph Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Arisaph Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Arisaph Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Arisaph Pharmaceuticals, Inc. - Pipeline Products Glance
Arisaph Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Arisaph Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Arisaph Pharmaceuticals, Inc. - Drug Profiles
ARI-3037MO
Product Description
Mechanism of Action
R&D Progress
ARI-2243
Product Description
Mechanism of Action
R&D Progress
ARI-1778
Product Description
Mechanism of Action
R&D Progress
ARI-2408
Product Description
Mechanism of Action
R&D Progress
ARI-3996
Product Description
Mechanism of Action
R&D Progress
ARI-4175
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Agonize GLP-1 for Type II Diabetes
Product Description
Mechanism of Action
R&D Progress
Tumor Activated Pro-Soft Drugs
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cancer
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Lipase for Atherosclerosis
Product Description
Mechanism of Action
R&D Progress
Arisaph Pharmaceuticals, Inc. - Pipeline Analysis
Arisaph Pharmaceuticals, Inc. - Pipeline Products by Target
Arisaph Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Arisaph Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Arisaph Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Arisaph Pharmaceuticals, Inc. - Recent Pipeline Updates
Arisaph Pharmaceuticals, Inc. - Dormant Projects
Arisaph Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Arisaph Pharmaceuticals, Inc., Key Information
Arisaph Pharmaceuticals, Inc., Key Facts
Arisaph Pharmaceuticals, Inc. - Pipeline by Indication, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
Arisaph Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
Arisaph Pharmaceuticals, Inc. - Phase II, 2015
Arisaph Pharmaceuticals, Inc. - Phase I, 2015
Arisaph Pharmaceuticals, Inc. - Preclinical, 2015
Arisaph Pharmaceuticals, Inc. - Discovery, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Target, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
Arisaph Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
Arisaph Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures
Arisaph Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
Arisaph Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
Arisaph Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll